Cost of Revenue Comparison: Dr. Reddy's Laboratories Limited vs Jazz Pharmaceuticals plc

Pharma Giants' Cost of Revenue: A Decade of Change

__timestampDr. Reddy's Laboratories LimitedJazz Pharmaceuticals plc
Wednesday, January 1, 201456369000000117418000
Thursday, January 1, 201562786000000102526000
Friday, January 1, 201662427000000105386000
Sunday, January 1, 201762453000000110188000
Monday, January 1, 201865724000000121544000
Tuesday, January 1, 201970421000000127930000
Wednesday, January 1, 202080591000000148917000
Friday, January 1, 202186645000000440760000
Saturday, January 1, 2022100551000000540517000
Sunday, January 1, 202342907000000435577000
Monday, January 1, 2024115557000000
Loading chart...

Data in motion

Cost of Revenue: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, Dr. Reddy's Laboratories Limited and Jazz Pharmaceuticals plc have shown contrasting trajectories in their cost of revenue from 2014 to 2023. Dr. Reddy's Laboratories, a major player in the Indian pharmaceutical industry, has seen a significant increase in its cost of revenue, peaking at approximately 115% growth from 2014 to 2024. This reflects their aggressive expansion and scaling of operations. In contrast, Jazz Pharmaceuticals, a global biopharmaceutical company, has maintained a more stable cost structure, with a modest increase of around 270% over the same period. Notably, 2023 data for Jazz Pharmaceuticals is missing, indicating potential reporting delays or strategic shifts. This comparison highlights the diverse strategies and market dynamics influencing these two pharmaceutical giants. As the industry evolves, understanding these financial trends is crucial for investors and stakeholders alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025